Polymorphism in CYP11α and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome;Polimorfismos en los genes CYP11α y CYP17 y etiologia del hiperandrogenismo en pacientes con poliquistosis ovarica

Medicina

Volumn 68, Issue 2, 2008, Pages 129-134

  Perez, Maria S ^a   Cerrone, Gloria E ^a   Benencia, Haydee ^b   Marquez, Norma ^b   De Piano, Eduardo ^b   Frechtel, Gustavo D ^a,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Clin of Endocrinol and Metabolism   (Argentina)

^c HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Androgens; Genetic polymorphism; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 17; TESTOSTERONE; STEROID 17ALPHA MONOOXYGENASE;

ADULT; ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; ANOVULATION; ARTICLE; CONTROLLED STUDY; ENDOCRINE DISEASE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; MULTIFACTORIAL INHERITANCE; OVARY POLYCYSTIC DISEASE; PHENOTYPE; POPULATION RESEARCH; TESTOSTERONE BLOOD LEVEL; BIOAVAILABILITY; CASE CONTROL STUDY; GENETIC MARKER; GENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANDROGENS; BIOLOGICAL AVAILABILITY; CASE-CONTROL STUDIES; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; FEMALE; GENETIC MARKERS; HUMANS; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE;

EID: 44449113753     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ramírez Luque M, San Millán J, Escobar Morreale. Genomic variants in polycystic ovary syndrome. Clínica Chimica Acta 2006; 366: 14-26.
2. Urbanek M, Legro RS, Driscoll DA, et al. Thirty seven genes for polycystic ovary syndrome: strongest evidence for linkage is with folistatin. Proc Natl Acad Sci USA 1999; 96: 8573-8.
3. Qin KN. Rosenfield RL. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol 1998; 145: 111-21.
4. Wood JR, Ho CK, Nelson-Degrave VL, McAllister JM, Strauss JF 3rd. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol 2004; 63: 51-60.
5. Nelson VL, Legro RS, Strauss JF, et al. Augmented androgens production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endo 1999; 13: 6946-57.
6. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Gen 1994; 3: 1873-6.
7. Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11α with polycystic ovary syndrome and hyperandrogenism. Hum Mol Gen 1997; 6: 397-402.
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74.
10. Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome. Fertil Steril 1990; 53: 785-91.
11. Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF 3rd McAllister JM. Differential activity of the cytochrome P450 17α hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 2000; 58: 2304-11.
12. Nelson VL, Legro RS, Strauss III JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13: 946-57.
13. Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side chain cleavage and 17alpha hydroxylase/C (17-20) lyase promoters. Fert Steril 2002; 77: 274-80.
14. San Millan JL, Sancho J, Calvo RM, Escobar Morreale HF. Role of the pentanucleotide (tttta), polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fert Steril 2001; 75: 797-802.
15. Mooser V, Mancini FP, Bopp S, et al. Sequence polymorphisms in the apo (a) gene associated with specific levels of Lp(a)in plasma. Hum Mol Genet 1995; 4: 173-81.
16. Gharani N, Waterworth DM, Williamson R, Franks S. 5′Polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovary. J Clin Endocrinol Metab 1996; 81: 4174.
17. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianatelli TC, Kouli CR. Microsatellite polymorphism (tttta)n at -528base pairs of gene CYP11α influences hyperandrogenemia in patients with polycystic ovary syndrome. Fert Ster 2000; 73: 735-41.